Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin versus metformin in women with polycystic ovary syndrome
2016-004435-20Phase 2Completed
- Sponsor
- Hull University Teaching Hospitals
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of empagliflozin in polycystic ovary syndrome (PCOS) (2 arms), sponsored by Hull University Teaching Hospitals. Primary endpoint: Endothelial function by reactive hyperaemia index. Started Jan 2017; status: completed.
02
Drugs
empagliflozin
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on 2016-004435-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004435-20.